Viatris Inc. completed a public offering of €650,000,000 in 4.250% Senior Notes due 2033 on June 17, 2026. The senior unsecured notes are guaranteed by Mylan Inc., Mylan II B.V., and Utah Acquisition Sub Inc. Net proceeds are intended to fund the repayment of the company's $1.675 billion 3.950% Senior Notes due 2026 and to replenish cash for general corporate purposes. The notes carry an annual interest rate of 4.250% and mature on June 17, 2033. Viatris is a global healthcare company that develops and manufactures generic and branded pharmaceutical products.
